Last reviewed · How we verify
NTQ1062 with Fulvestrant — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
NTQ1062 with Fulvestrant (NTQ1062 with Fulvestrant) — Nanjing Chia-tai Tianqing Pharmaceutical.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| NTQ1062 with Fulvestrant TARGET | NTQ1062 with Fulvestrant | Nanjing Chia-tai Tianqing Pharmaceutical | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- NTQ1062 with Fulvestrant CI watch — RSS
- NTQ1062 with Fulvestrant CI watch — Atom
- NTQ1062 with Fulvestrant CI watch — JSON
- NTQ1062 with Fulvestrant alone — RSS
Cite this brief
Drug Landscape (2026). NTQ1062 with Fulvestrant — Competitive Intelligence Brief. https://druglandscape.com/ci/ntq1062-with-fulvestrant. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab